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Transcatheter Aortic Valve Implantation for
Failing Surgical Aortic Bioprosthetic Valve
From Concept to Clinical Application and Evaluation (Part 2)
Nicolo Piazza, MD,* Sabine Bleiziffer, MD,* Gernot Brockmann, MD,*
Ruge Hendrick, MD,* Marcus-André Deutsch, MD,* Anke Opitz, MD,*
Domenico Mazzitelli, MD,* Peter Tassani-Prell, MD, PHD,† Christian Schreiber, MD,*
Rüdiger Lange, MD, PHD*
Munich, Germany
Objectives This study sought to review the acute procedural outcomes of patients who underwent
transcatheter aortic valve (TAV)–in–surgical aortic valve (SAV) implantation at the German Heart Cen-
ter, Munich, and to summarize the existing literature on TAV-in-SAV implantation (n  47).
Background There are several case reports and small case series describing transcatheter aortic
valve implantation for a failing surgical aortic valve bioprosthesis (TAV-in-SAV implantation).
Methods From January 2007 to March 2011, 20 out of 556 patients underwent a TAV-in-SAV im-
plantation at the German Heart Center Munich. Baseline characteristics and clinical outcome data
were prospectively entered into a dedicated database.
Results The mean patient age was 75  13 years, and the mean logistic European System for Car-
diac Operative Risk Evaluation and Society of Thoracic Surgeons’ Risk Model scores were 27  13%
and 7  4%, respectively. Of the 20 patients, 14 had stented and 6 had stentless surgical biopros-
theses. Most cases (12 of 20) were performed via the transapical route using a 23-mm Edwards Sa-
pien prosthesis (Edwards Lifesciences, Irvine, California). Successful implantation of a TAV in a SAV
with the patient leaving the catheterization laboratory alive was achieved in 18 of 20 patients. The
mean transaortic valve gradient was 20.0  7.5 mm Hg. None-to-trivial, mild, and mild-to-moderate
paravalvular aortic regurgitation was observed in 10, 6, and 2 patients, respectively. We experienced
1 intraprocedural death following pre-implant balloon aortic valvuloplasty (“stone heart”) and 2 fur-
ther in-hospital deaths due to myocardial infarction.
Conclusions TAV-in-SAV implantation is a safe and feasible treatment for high-risk patients with
failing aortic bioprosthetic valves and should be considered as part of the armamentarium in the
treatment of aortic bioprosthetic valve failure. (J Am Coll Cardiol Intv 2011;4:733–42) © 2011 by
the American College of Cardiology Foundation
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TAV-In-SAV
734In 2007, Wenaweser et al. (1)
reported the first case of a trans-
catheter valve (Medtronic Core-
Valve system, Medtronic, Min-
neapolis, Minnesota) implanted
into a degenerated surgical aortic
bioprosthesis. Since then, nu-
merous case reports of trans-
catheter aortic valve (TAV)–in–surgical aortic valve (SAV)
implantation (TAV-in-SAV) have been described with
either the Medtronic CoreValve or Edwards Sapien (Ed-
wards Lifesciences, Irvine, California) bioprosthesis (2–19).
TAV-in-SAV is typically reserved for high surgical risk
patients requiring redo surgery. Nonetheless, the Medtronic
CoreValve and Edwards Sapien devices were not designed
nor indicated for failing surgical bioprostheses.
Figure 1. Munich Case #299: Transapical 23-mm Edwards Sapien Implante
(A) Fluoroscopic identiﬁcation of the Sorin Soprano (Sorin, Saluggia, Italy) biop
tioning of the Edwards Sapien (Edwards Lifesciences, Irvine, California) valve 2
Abbreviations
and Acronyms
SAV  surgical aortic valve
TAV  transcatheter aortic
valve
TAVI  transcatheter aortic
valve implantationtography demonstrated trivial aortic regurgitation.The aim of this paper is to report on the acute clinical
results of 20 patients who underwent TAV-in-SAV
implantation at the German Heart Center, Munich.
Furthermore, we provide a review of published case
reports and case series on TAV-in-SAV implantation
(n  47 cases).
Methods
Between June 2007 and March 2011, 556 patients under-
went transcatheter aortic valve implantation (TAVI) at the
German Heart Center, Munich. High surgical risk patients
with severe native aortic valve stenosis or failing surgical
aortic bioprostheses were referred for TAVI after a dedi-
cated team of cardiac surgeons, cardiologists, and anesthe-
siologists reached consensus that TAVI was in the best
22-mm Sorin Soprano Bioprosthesis
sis. (B) Pre-implant balloon valvuloplasty. (C) Contrast aortography and posi-
m below the base ring of the Sorin Soprano valve. (D) Final contrast aor-d in a
rosthe
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735interest of the patient. Patients with stented or stentless
aortic valve prostheses with internal diameters between 18
and 27 mm were considered for TAV-in-SAV implanta-
tion. Anatomical criteria for TAV-in-SAV were confirmed by
a combination of imaging modalities: transesophageal echo-
cardiography, multislice computed tomography, and angiogra-
phy. Informed consent was obtained from all patients.
Device description and procedure. Details of the Medtronic
oreValve and Edwards Sapien devices and technical as-
ects of the procedure have been previously published.
rocedures were performed in a hybrid surgical suite
20,21). Depending on underlying comorbidities, patients
eceived either general anesthesia or local anesthesia (with
ild sedation).
Deﬁnition of outcomes. Procedural success was defined by
Figure 2. Munich Case #371: Transapical 26-mm Edwards Sapien Implante
(A) Fluoroscopic identiﬁcation of the Carpentier-Edwards (CE) Perimount (Edw
Sapien valve 2 to 4 mm below the base ring of the CE Perimount valve. (C) M
appearance). (D) Final contrast aortography revealed no aortic regurgitation.successful implantation of a TAV in a SAV with the patient 5leaving the catheterization laboratory alive. Echocardiogra-
phy and invasive hemodynamic pressure recordings pro-
vided in-hospital transaortic valve gradients. Aortic regur-
gitation was evaluated by echocardiography and contrast
aortography and classified as none, mild, moderate, or
severe.
Statistical analyses. Continuous variables are described as
mean  SD, and dichotomous or nominal variables are
described as numbers and percentages. Statistical analyses
were performed using SPSS (version 17.0 for Windows,
SPSS Inc., Chicago, Illinois).
Results
Baseline characteristics. From January 2007 to March 2011,
23-mm CE Perimount
ifesciences, Irvine, California) bioprosthesis. (B) Positioning of the Edwards
loyment phase of the Edwards Sapien valve (balloon has a “dumb-bell”d in a
ards L
id-dep56 patients underwent TAVI at the German Heart
Table 1. German Heart Center, Munich, Clinical Experience With the TAV-In-SAV Procedure Since 2007 (n  20)
Case
Number Patient Characteristics
Vascular Access, Type and Size of Transcatheter Valve/
Surgical Bioprosthesis/Presenting Pathology Procedural Details Immediate Results and Additional Comments
1 (#146) 83-year-old woman, LES 30%, STS 6% TA 23-mm Edwards Sapien 2/23-mm Sorin Mitroﬂow
implanted 7 years prior/AS (MG 46 mm Hg)
1. Pre-implant BAV With 20 mm balloon
2. Rapid pacing during deployment
3. Second 23-mm Edwards Sapien implanted
Mild paravalvular AR/MG 44 mm Hg. Moderate-severe
central AR after the ﬁrst 23-mm Edwards Sapien
implantation. After the second 23-mm Edwards
Sapien, there was mild AR although the mean
gradient was 44 mm Hg.
2 (#153) 40-year-old man, LES 6%, STS 3% TF 29-mm Medtronic CoreValve/Homograft implanted
1 year prior/AR
1. No pre-implant BAV
2. No rapid pacing during deployment
Not successful. CoreValve prosthesis dislocated 2
while semideployed. In both instances, CoreValve
prosthesis was retrieved from the body. Procedure
aborted and patient underwent successful surgical
valve replacement.
3 (#286) 75-year-old woman, LES 24%, STS 16% TA 23-mm Edwards Sapien/23-mm Carpentier-Edwards
Perimount/AR
1. No pre-implant BAV Mild-moderate paravalvular AR/MG 17 mm Hg.
2. Rapid pacing during deployment
4 (#299) 73-year-old woman, LES 33%, STS 3% TA 23-mm Edwards Sapien/22-mm Sorin Soprano
implanted 6 years prior/AS (MG 64 mm Hg)
1. Pre-implant BAV with 20-mm balloon
2. Rapid pacing during deployment
Trivial paravalvular AR/MG 15 mm Hg.
5 (#309) 79-year-old man, LES 30%, STS 8% TA 23-mm Edwards Sapien/21-mm Medtronic Mosaic
implanted 5 years prior/AS (MG 66 mm Hg)
1. Pre-implant BAV with 22-mm balloon
2. Rapid pacing during deployment
No AR/MG 20 mm Hg. Left main occlusion
following transcatheter aortic valve implantation
followed by successful left main coronary stenting
(in-hospital death within 30 days).
6 (#315) 75-year-old man, LES 28%, STS 6% TF 26-mm Medtronic CoreValve and TA 23-mm Edwards
Sapien/24-mm Sorin Soprano implanted 4 years prior/AS
(MG 64 mm Hg)
1. Pre-implant BAV with 22-mm balloon
2. No rapid pacing during deployment
3. Post-implant BAV with 22-mm balloon for
moderate-severe AR
4. 23-mm Edwards Sapien implanted
Mild-moderate paravalvular AR/MG 20 mm Hg.
Moderate-severe paravalvular AR was noted after
implantation of the ﬁrst 26-mm CoreValve. A
23-mm Edwards Sapien prosthesis was implanted
within the CoreValve prosthesis and angiography
subsequently demonstrated mild-moderate
paravalvular AR. A myocardial infarction was
diagnosed on day 2 after procedure (in-hospital
death within 30 days).
7 (#342) 67-year-old man, LES 7%, STS 5% TA 26-mm Edwards Sapien/25-mm Carpentier-Edwards
Perimount implanted 3 years prior/AS (MG 51 mm Hg)
1. Pre-implant BAV with 20-mm balloon
2. Rapid pacing during deployment
Mild paravalvular AR/MG 25 mm Hg
8 (#355) 91-year-old man, LES 52%, STS 11% No attempt made to deploy transcatheter valve/23-mm
Carpentier Edwards Perimount implanted 5 years prior/ AS
(MG 53 mm Hg)
1. Pre-implant BAV 20-mm balloon Not successful. Following BAV, severe left ventricular
dysfunction, hemodynamic instability, and cardiac
arrest without recovery (intraprocedural death).
9 (#371) 75-year-old woman, LES 26%, STS 4% TA 26-mm Edwards Sapien/23-mm Carpentier-Edwards
Perimount Magna implanted 7 years prior/AS
(MG 77 mm Hg)
1. Pre-implant BAV with 20-mm balloon
2. Rapid pacing during deployment
No AR/MG 24 mm Hg
10 (#376) 87-year-old woman, LES 27%, STS 8% TA 23-mm Edwards Sapien/21-mm Medtronic Mosaic
implanted 8 years prior/AR
1. Pre-implant BAV with 20-mm balloon
2. Rapid pacing during deployment
No AR/MG 14 mm Hg
11 (#401) 80-year-old woman, LES 28%, STS 6% TA 26-mm Edwards Sapien/25-mm BioValsalva implanted 4
years prior/AR
1. No pre-implant balloon dilation
2. Rapid pacing during deployment
No AR/MG 20 mm Hg
12 (#415) 71-year-old woman, LES 13%, STS 6% TA 23-mm Edwards Sapien/21-mm Medtronic Freestyle
[stentless] implanted 4 years prior/AR
1. Pre-implant BAV with 20-mm balloon
2. Rapid pacing during deployment
No AR/MG 19 mm Hg
Continued on next page
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Table 1. Continued
Case
Number Patient Characteristics
Vascular Access, Type and Size of Transcatheter Valve/
Surgical Bioprosthesis/Presenting Pathology Procedural Details Immediate Results and Additional Comments
13 (#416) 79-year-old woman, LES 58%, STS 7% TA 23-mm Edwards Sapien/23-mm Sorin Mitroﬂow
implanted 7 years prior/combined AR and AS
(MG 31 mm Hg)
1. No pre-implant balloon dilation
2. Rapid pacing during deployment
No AR/MG 16 mm Hg
14 (#450) 71-year-old man, LES 17% STS 2% TA 23-mm Edwards Sapien 1 and TF 23-mm Edwards
Sapien 1/23-mm St. Jude Medical Toronto, Freestyle
[stentless] implanted 4 years prior/AR
1. No pre-implant BAV
2. Rapid pacing during deployment
Mild paravalvular leak immediately following
implantation. After transapical closure,
echocardiography identiﬁed new severe central AR
due to a malcoapting leaﬂet in the noncoronary
sinus position. Patient underwent transfemoral
implantation of a second 23-mm Edwards Sapien.
No AR/MG
15 (#453) 71-year-old woman, LES 11%, STS 3% TA 23-mm Edwards Sapien/21-mm homograft implanted
14 years prior/AR
1. No pre-implant balloon dilation
2. Rapid pacing during deployment
No AR/MG 17 mm Hg
16 (#464) 89-year-old man, LES 23%, STS 10% TA 26-mm Edwards Sapien/27-mm Biocor  aortic root
replacement 16 years prior/AR
1. No pre-implant BAV
2. Rapid pacing during deployment
Mild AR/MG 20 mm Hg
17 (#468) 82-year-old woman, LES 37%, STS 7% TA 23-mm Carpentier-Edwards Sapien/23-mm Carpentier-
Edwards Perimount Magna implanted 3 years prior/AS
(MG 65 mm Hg)
1. Pre-implant BAV with 20 mm balloon
2. Rapid pacing during deployment
Mild AR/MG N/A
18 (#481) 62-year-old man, LES 7%, STS 3% TF 29-mm CoreValve/Surgical stented bioprosthesis in 1985
and 27-mm homograft implanted 15 years
prior/AR
1. No pre-implant BAV
2. Rapid pacing during deployment
Mild AR/invasive PG 11 mm Hg
19 (#499) 79-year-old woman, LES 18%, STS 5% TA 23-mm Edwards Sapien XT/23-mm Carpentier-Edwards
Perimount implanted 10 years prior/AS
(MG 63 mm Hg)
1. Pre-implant BAV with 20-mm balloon
2. Rapid pacing during deployment
No AR/MG 18 mm Hg
20 (#502) 76-year-old female, LES 7%, STS 3% TA 23-mm Edwards Sapien XT/21-mm Carpentier-Edwards
Perimount/AS (MG 67 mm Hg)
1. Pre-implant BAV with 20-mm balloon
2. Rapid pacing during deployment
No AR/MG N/A
Biocor and Toronto are products of St. JudeMedical (Minneapolis, Minnesota). BioValsalva (Vascutek, Terumo, Newmains, Scotland). CoreValve, Freestyle, andMosaic are products ofMedtronic CV Luxembourg s.a.r.l. (Tolochenaz, Switzerland) orMedtronic (Minneapolis,
Minnesota). Mitroflow and Soprano are products of Sorin Group (Saluggia, Italy). Perimount and Sapien are products of Edwards Lifesciences (Irvine, California).
AR aortic regurgitation; AS aortic stenosis; BAV balloon aortic valvuloplasty; LES logistic European System for Cardiac Operative Risk Evaluation; MGmean gradient; N/A not available; PG peak gradient; SAV surgical aortic valve; STS Society of
Thoracic Surgeons predicted risk of mortality score; TA transapical; TAV transcatheter aortic valve; TF transfemoral.
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Table 2. Summary Table of Published Case Reports and Case Series of TAV-In-SAV Procedures Since 2007 (n  47)
First Author (Ref. #) Patient Characteristics
Vascular Access, Type and Size of Transcatheter Valve/
Surgical Bioprosthesis/Presenting Pathology Procedural Details Results
Wenaweser et al. (1) 80-year-old man, LES 36% TF 26-mm Medtronic CoreValve/23-mm Sorin Mitroﬂow/AR 1. No Pre-implant BAV
2. No rapid pacing during deployment
No AR/MG 12 mm Hg
Walther et al. (2) 82-year-old woman, LES 21%, STS 9.2% TA 23-mm cuffed Edwards Sapien/21-mm Carpentier-
Edwards Perimount/AS
1. Pre-implant BAV (balloon size N/A)
2. Rapid pacing during deployment
No AR/MG 17 mm Hg
Klaaborg et al. (3) 82-year-old woman, LES 53% TA 23-mm Edwards Sapien/21-mm Sorin Mitroﬂow/AS 1. Pre-implant BAV (23-mm balloon)
2. Rapid pacing during deployment
Trivial transvalvular AR/PG 40 mm Hg
Kelpis et al. (4) 80-year-old man, LES 37.3%, STS 27.5% TA 23-mm Edwards Sapien/25-mm St. Jude Toronto
stentless/AR
1. Pre-implant BAV (20-mm balloon)
2. Rapid pacing during deployment
No AR “good hemodynamic function”
Rodés-Cabau et al. (22) 84-year-old woman, STS 48% TA 23-mm Edwards Sapien/23-mm Medtronic Freestyle
[stentless]/AR
1. No pre-implant BAV
2. Rapid pacing during deployment
Trivial AR/MG 17 mm Hg
Attias et al. (5) 80-year-old man, LES 26%, STS 18% TF 29-mm Medtronic CoreValve/25-mm stentless Xenograft
(manufacturer not reported)/AR
1. No pre-implant BAV
2. No rapid pacing during deployment
No AR/MG 3 mm Hg
Schmoeckel et al. (6) 72-year-old man, LES 26%, STS 18% TA 26-mm Edwards Sapien/24-mm aortic allograft as a
miniroot (manufacturer not reported)/AR
1. Pre-implant BAV (balloon size N/A)
2. Rapid pacing during deployment
Trivial paravalvular AR/PG 9 mm Hg
Ussia et al. (7) 85-year-old woman, LES 45% TF 26-mm Medtronic CoreValve/21-mm St. Jude Biocor
[stentless]/AR
1. No pre-implant BAV
2. Rapid pacing during deployment
3. Post-implant dilation with 25-mm
nucleus balloon
Moderate-severe paravalvular AR
(reduced to moderate with post-
implant dilation)
Napodano et al. (8) 84-year-old woman, LES 31.8% TF 29-mm Medtronic CoreValve/25-mm St. Jude Biocor
[stentless]/AR
1. No pre-implant BAV
2. Rapid pacing during deployment
3. Post-implant dilation with 25-mm
nucleus balloon
Trivial paravalvular AR “no transvalvular
gradient”
Attias et al. (9) 70-year-old man, LES 35% TF 26-mm Medtronic CoreValve/21-mm Carpentier-Edwards
Perimount/AR
Information not provided No AR/No information provided for
gradient
Ng et al. (10) 82-year-old man, LES 28% TA 26-mm Edwards Sapien/23-mm Medtronic Freestyle
[stentless]/AR
1. No information about BAV
2. Rapid pacing during deployment
3. 2 Edwards Sapiens implanted
Severe transvalvular AR after ﬁrst valve
implantation. A second 26-mm
Edwards device was implanted and
associated with mild transvalvular AR
Olsen et al. (23) 86-year-old man, LES 30%
(2 previous cardiac operations)
Right subclavian artery 29-mm Medtronic CoreValve/
23-mm homograft [stentless]/AR
1. No information about BAV
2. No information on rapid pacing
No information available about post-
implant AR or transvalvular gradient
Dainese et al. (11) 48-year-old woman, LES 12%
(3 previous cardiac operations)
TA 23-mm Edwards Sapien/21-mm CryoLife Bravo 400
[stentless] for miniroot technique/AS
1. Pre-implant BAV
2. Rapid pacing during deployment
No AR/PG 18 mm Hg
Sharp et al. (12) 82-year-old man, LES 64%, STS 46% Left subclavian artery 23-mm Edwards Sapien/
23-mm Medtronic Freestyle [stentless]/AR
1. No pre-implant BAV
2. Rapid pacing during deployment
No AR/MG 10 mm Hg and PG 24 mm Hg
Ferrari et al. (14) 80-year-old woman, LES 59% TA 23-mm Edwards Sapien/23-mm Sorin Mitroﬂow/AR 1. No pre-implant BAV
2. Rapid pacing during deployment
No AR/MG 10 mm Hg and PG 18 mm Hg
Maroto et al. (15) (n  2) 84-year-old man, LES 25% TA 23-mm Edwards Sapien/25-mm Medtronic Hancock
standard/combined AS and AR
1. No pre-implant BAV
2. Rapid pacing during deployment
Minimal transvalvular AR/PG 17 mm Hg
84-year-old man, LES 18% TA 23-mm Edwards Sapien/25-mm Medtronic, Hancock
standard/combined AS and AR
1. No pre-implant BAV
2. Rapid pacing during deployment
Minimal transvalvular AR/PG 13 mm Hg
Continued on next page
J
A
C
C
:
C
A
R
D
IO
V
A
S
C
U
L
A
R
IN
T
E
R
V
E
N
T
IO
N
S
,
V
O
L
.
4
,
N
O
.
7
,
2
0
1
1
J
U
L
Y
2
0
1
1
:7
3
3
–
4
2
P
iazza
et
al.
TA
V-In-S
A
V
7
3
8
Table 2. Continued
First Author (Ref. #) Patient Characteristics
Vascular Access, Type and Size of Transcatheter Valve/
Surgical Bioprosthesis/Presenting Pathology Procedural Details Results
Khawaja et al. (16) (n  4) 66-year-old man, LES 25% TF 26-mm Medtronic CoreValve/21-mm Sorin Mitroﬂow/
combined AS and AR
1. No pre-implant BAV
2. Rapid pacing during deployment
No AR/PG 30 mm Hg
76-year-old man, LES 19% TF 26-mm Medtronic CoreValve/23-mm Carpentier-Edwards
Perimount/AR
1. No pre-implant BAV
2. Rapid pacing during deployment
No AR/PG 39 mm Hg
85-year-old woman, LES 38% TF 26-mm Medtronic CoreValve/Carpentier-Edwards
Perimount (size not available)/AR
1. No pre-implant BAV
2. Rapid pacing during deployment
Mild paravalvular AR/PG 30 mm Hg
48-year-old woman, LES 12% TF 26-mm Medtronic CoreValve/25-mm CryoLife O’Brien
[stentless]/AS
1. No pre-implant BAV
2. Rapid pacing during deployment
3. Post-implant dilation with 20-mm
balloon
Mild paravalvular AR/PG 35 mm Hg
Webb et al. (17) (n  10)* 87-year-old, LES 31%, STS 10% TA 23-mm Edwards Sapien/25-mm Carpentier-Edwards
Perimount/combined AS and AR
No speciﬁc details except that authors
state that pre-implant BAV is
avoided in patients with
predominant AR and encouraged in
those with AS
No AR/MG 11 mm Hg
83-year-old, LES 38%, STS 10% TA 23-mm Edwards Sapien/23-mm Carpentier-Edwards
Perimount/combined AS and AR
No AR/MG 24 mm Hg
85-year-old LES 39%, STS 12% TA 23-mm Edwards Sapien/23-mm Carpentier-Edwards
Perimount/AS
No AR/MG 27 mm Hg
86-year-old, LES 33%, STS 11% TA 23-mm Edwards Sapien/21-mm Ionescu-Shiley
standard/AS
No AR/MG 23 mm Hg
86-year-old, LES 33%, STS 10% TA 26-mm Edwards Sapien/25-mm Carpentier-Edwards
Perimount/AS
No AR/MG 13 mm Hg
83-year-old, LES 46%, STS 11% TA 23-mm Edwards Sapien/21-mm Carpentier-Edwards
Perimount/AS
Mild AR/MG 24 mm Hg
78-year-old, LES 20%, STS 5% TA 23-mm Edwards Sapien/21-mm Shelhigh
SuperStentless/AS
No AR/MG 16 mm Hg
84-year-old, LES 24%, STS 12% TA 23-mm Edwards Sapien/21-mm Medtronic
Freestyle/AR
No AR/MG 11 mm Hg
82-year-old, LES 34%, STS 11% TA 23-mm Edwards Sapien/21-mm Medtronic
Mosaic/combined AS and AR
No AR/MG 30 mm Hg
67-year-old, LES 14%, STS 16% TF 23-mm Edwards Sapien/23-mm Carpentier-Edwards
Perimount/combined AS and AR
Mild AR/MG 21 mm Hg
Seiffert et al. (19) (n  4) 83-year-old man, LES 89%, STS 35% TA 23-mm Edwards Sapien/23-mm St. Jude Biocor
[stentless]/AS
1. No pre-implant BAV
2. Rapid pacing during deployment
AR grade N/A/MG 20 mm Hg
78-year-old man, LES 52%, STS 30% TA 23-mm Edwards Sapien/21-mm Medtronic Hancock
standard/AS
1. No pre-implant BAV
2. Rapid pacing during deployment
No AR/MG 30 mm Hg
88-year-old man, LES 42%, STS 20% TA 23-mm Edwards Sapien/23-mm Medtronic Hancock
standard/AR
1. No pre-implant BAV
2. Rapid pacing during deployment
Mild paravalvular AR/MG 12 mm Hg
73-year-old man, LES 48%, STS 17% TA 23-mm Edwards Sapien/25-mm Medtronic Hancock
II/AS
1. No pre-implant BAV
2. No rapid pacing during deployment
No AR/MG 12 mm Hg
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740Center, Munich. Of those, 20 patients with a failing surgical
bioprosthesis underwent a TAV-in-SAV procedure. Base-
line and procedural characteristics and outcomes are sum-
marized in Table 1.
The mean patient age was 75  13 years and the mean
logistic European System for Cardiac Operative Risk Eval-
uation and Society of Thoracic Surgeons’ Risk Model scores
were 27 13% and 7 4%, respectively. Patients presented
on average 5  2 years after their primary valve operation.
Of the 20 patients, 14 had stented and 6 had stentless surgical
bioprostheses. Primary aortic stenosis, aortic regurgitation, and
combination aortic stenosis/regurgitation were present in 10, 9,
and 1 patient, respectively.
Procedural characteristics and clinical outcomes. Most cases
12 of 20) were performed via the transapical route using
23-mm Edwards Sapien prosthesis. Pre-implant bal-
oon aortic valvuloplasty was performed in those patients
ith primary aortic stenosis but not in those with primary
ortic regurgitation. Procedural success was achieved in
8 of 20 patients (see “Unsuccessful TAV-in-SAV im-
lantations” section). The mean post-procedural transaortic
alve gradient was 20.0  7.5 mm Hg. Except for Case
146, who underwent implantation of 2 23-mm Edwards
apien bioprostheses, all patients had a post-procedural
ransaortic valve gradient below 25 mm Hg. None-to-
rivial, mild, and mild-to-moderate paravalvular aortic
egurgitations were observed in 10, 6, and 2 patients,
espectively.
No patient experienced a stroke or need for permanent
acemaking. Figures 1 and 2 demonstrate the fluoroscopic
mages of 2 successful TAV-in-SAV procedures.
Unsuccessful TAV-in-SAV implantations. A TAV was not
implanted in 2 of the 20 TAV-in-SAV patients. In the
first patient with a failing homograft and severe aortic
regurgitation (Case #153), the CoreValve prosthesis dis-
located into the ascending aorta on 2 attempts; in both
instances, the prosthesis was retrieved from the body in
its semideployed state. The procedure was aborted and
the patient underwent successful conventional aortic
valve replacement. In this case, we did not use rapid
pacing during valve deployment. The large stroke vol-
umes likely contributed to the instability of the prosthesis
during valve deployment. Rapid pacing during valve
deployment is routinely used in patients with severe
aortic regurgitation. In the second case (#355), a “stone
heart” developed after pre-implant balloon aortic valvu-
loplasty leading to intraprocedural death despite imme-
diate institution of cardiopulmonary bypass.
In-hospital deaths. There were 2 in-hospital post-
procedural deaths (Cases #309 and #315). In Case #309,
immediate left main coronary occlusion occurred after
deployment of the 23-mm Edwards Sapien within a
21-mm Medtronic Mosaic valve (Fig. 3). Despite suc-
cessful left main coronary stenting, the patient died onT
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741hospital day 2 from multiorgan failure. In fact, pre-
procedural imaging revealed “bulky calcifications” of the
native aortic valve and a surgical stent post overlying the ostium
of the left main coronary artery (Fig. 3). The orientation of the
stent posts relative to the coronary ostia is now assessed
regularly (Fig. 3D). In Case #315, moderate-to-severe para-
valvular aortic regurgitation was documented after implanting
a 26-mm CoreValve into a 24-mm Sorin Soprano (Sorin
Group, Saluggia, Italy) bioprosthesis. A 23-mm Edwards
Sapien was subsequently implanted within the 26-mm Core-
Valve. Despite a reduction in the aortic regurgitation grade, the
patient died on hospital day 3 from cardiogenic shock; a
myocardial infarction was suspected based on rising cardiac
biomarkers.
TAV-in-SAV implantation. A SUMMARY OF PUBLISHED CASE
ERIES AND CASE REPORTS. We performed a search in
Figure 3. Munich Case #309: A Transapical 23-mm Edwards Sapien Implan
(A) Parasagittal multislice computed tomography view demonstrates the st
thesis overlying the ostia of the left main coronary artery. (B) Contrast aort
left coronary sinus. (C) After deployment of the Edwards Sapien valve, ther
multislice computed tomography view demonstrating normal orientation o
routinely performed before transcatheter aortic valve–in–surgical aortic valPubMed for peer-reviewed papers on TAV for failingsurgical bioprosthetic valves. From January 2007 to January
2011, 47 cases of TAV-in-SAV were identified in either
case report or case series format (Table 2) (22,23).
Salient features of these case reports can be summarized
as follows. Patients were typically elderly and at high or
prohibitive surgical risk. They presented 6 to 26 years after
their primary valve operation. A significant number of
patients presented with severe aortic regurgitation, which is
atypical for patients currently undergoing TAVI. Patients
had a prior history of either stented or stentless valve
replacement (labeled valve size: 21 to 25 mm). The “smaller”
23-mm Edwards Sapien and “smaller” 26-mm CoreValve
prostheses were implanted in the vast majority of reported
cases. Heterogeneous practice patterns were apparent with
respect to the use of pre-implant balloon aortic valvuloplasty
and/or rapid pacing during valve deployment. Significant
a 21-mm Medtronic Mosaic Bioprosthetic Valve
ost of the Medtronic Mosaic (Medtronic, Tolochenaz, Switzerland) biopros-
hy demonstrates a large calciﬁc mass (radiolucent) in the region of the
immediate obstruction of the left main coronary ostia. (D) Short-axis
rosthesis stent posts relative to coronary ostia. This examination is now
lantation.ted in
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742were observed with either the Edwards Sapien or CoreValve
bioprosthesis. In some cases, however, the transvalvular
gradient remained considerably elevated (20 mm Hg).
Nevertheless, the investigators noted that there was
adequate improvement in valve function to positively
influence the quality of life in these otherwise “high or
prohibitive” surgical risk patients.
The average transaortic valve gradient after primary
aortic valve surgery with the Carpentier-Edwards Peri-
mount bioprosthesis (Edwards Lifesciences) has been
reported to be approximately 14  6 mm Hg (24). In our
ohort, the average transaortic valve gradient following
AV-in-SAV was 20.0  7.5 mm Hg.
Coronary obstruction following TAV-in-SAV implan-
ation is a rare but life-threatening complication that
equires immediate cardiopulmonary resuscitation and
einstitution of coronary blood flow. A recent publica-
ion described 2 cases of coronary obstruction during
reatment of a degenerated Mitroflow (Sorin) biopros-
heses (25). This may suggest that certain surgical bio-
rostheses may increase the risk of coronary obstruction
n the setting of TAV-in-SAV implantation. In our experi-
nce, we observed coronary obstruction in treating a degener-
ted Medtronic Hancock bioprosthesis. We did not observe,
owever, coronary obstruction while treating 2 Sorin Soprano
nd 2 Sorin Mitroflow bioprostheses.
onclusions
TAV-in-SAV implantation is currently considered an
off-label indication. At this time, both Medtronic Cor-
eValve and Edwards Lifesciences are pursuing TAV-in-
SAV expanded eligibility trials for CE mark approval. If
the promising findings here are confirmed in larger
studies with longer follow-up, TAV-in-SAV implanta-
tion may become an alternative in high risk redo surgery
patients.
Reprint requests and correspondence: Dr. Nicolo Piazza, Car-
diovascular Surgery Department, German Heart Center Munich,
Lazarettstrasse 36, 80636 Munich, Germany. E-mail: nicolopiazza@
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